Ryan Labs Company Profile
✉ Email this page to a colleague
What is the competitive landscape for RYAN LABS, and what generic and branded alternatives to RYAN LABS drugs are available?
RYAN LABS has five approved drugs.
Drugs and US Patents for Ryan Labs
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ryan Labs | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 201942-002 | Nov 18, 2021 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Ryan Labs | VALSARTAN | valsartan | TABLET;ORAL | 218169-001 | Aug 5, 2024 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Ryan Labs | LATANOPROST | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 202077-001 | Feb 11, 2013 | AT | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Ryan Labs | VALSARTAN | valsartan | TABLET;ORAL | 218169-003 | Aug 5, 2024 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Ryan Labs | VIGABATRIN | vigabatrin | TABLET;ORAL | 215519-001 | Apr 28, 2023 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Ryan Labs | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 201942-001 | Nov 18, 2021 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Ryan Labs | VALSARTAN | valsartan | TABLET;ORAL | 218169-002 | Aug 5, 2024 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.